Please use a PC Browser to access Register-Tadawul
Get It
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio Of Degrader Medicines Pursuing Targets Of High Unmet Need In Oncology; Says Cash Runway Expected To Fund Operations Into 2027
C4 Therapeutics, Inc. CCCC | 1.91 | +4.37% |
